


Disclosures

Dr Pitt has served as a consultant for Bayer, Boehringer Ingelheim, KBP Biosciences, Astra Zeneca, Sarfez, SC Pharmaceuticals, SQ Innovation, G-3 Pharmaceuticals, Vifor, Corteria Pharmaceuticals, Proton Intel, Brainstorm Medical, and Lexicon, and holds stock options for US patent 9931412 (site-specific delivery of eplerenone to the myocardium) and US patent pending 63/045,783 (histone acetylation modulating agents for the prevention and treatment of organ damage). Dr Williams has served as a consultant for KBP Biosciences, Relapsa, Unicycive, Damian, Crinetics, Cereno Scientific, and Alnylam.

REFERENCES

1. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. *Ann Intern Med.* 2020;173:10–20. doi: 10.7326/M20-0065
2. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal disease. *Hypertension.* 2015;65:257–263. doi: 10.1161/HYPERTENSIONAHA.114.04488
3. Ding K, Li Z, Lu Y, Sun L. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease. *Eur J Intern Med.* 2023;115:114–127. doi: 10.1016/j.ejim.2023.05.038
4. Freeman MW, Halvorsen Y-D, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, et al; BrigHTN Investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension. *N Engl J Med.* 2023;388:395–405. doi: 10.1056/NEJMoa2213169
5. Treesaranuwattana T, Wong KYH, Brooks DL, Tay CS, Williams GH, Williams JS, Pojoga LH. Lysine-specific demethylase-1 deficiency increases agonist signaling via the mineralocorticoid receptor. *Hypertension.* 2020;75:1045–1053. doi: 10.1161/HYPERTENSIONAHA.119.13821



Tehran Medical School, Tehran, Iran

More than 170 years ago, in 1851, supported by Mirza-taghi-khan Farahani (Figure [A]), also known as Amir Kabir, chief minister of Iran, the first school of new and modern science and technology was opened in Tehran city. This school was named Dar-ol-Fonun (Figure [B]).

Teaching modern medicine was one of the main educational programs at Dar-ol-Fonun (Figure [C]) and Dr Jakob Eduard Polak (1818–1891) (Figure [D]), Austrian physician, was responsible for medical education.

In 1916, Dr Mohamad-Hosein Loghman Adham (1879–1950) (Figure [E]), known as Loghman-ol-Doleh, was appointed as the head of the medical curriculum and carried out important and fundamental work for the development of medical education. With his efforts, medical education programs evolved from a class to a medical school.

In February 4, 1935, the new building of Tehran Medical School (Figure [F]) was opened in Tehran city, and Dr Loghman Adham was elected as its chairman. Autopsy hall was the first part of the new building to be opened (Figure [G]).

Dr Abol-ghasem Bakhtyar (1872–1971) (Figure [H]) and Dr Amir Alam (1876–1961) (Figure [I]), together with Dr Loghman Adham, were the founders of Tehran Medical School. They devoted tremendous effort to equip and set up anatomy training and the autopsy hall.

Today, Tehran Medical School, more than 170 years after its opening, is considered the most prominent and largest medical center in Iran (Figure [J]).

Hossein Shahzadi, MD

Department of Pediatric Cardiology, Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran